Salud financiera de hoja de balance de Chimerix

Salud financiera controles de criterios 6/6

Chimerix tiene un patrimonio de los accionistas total de $135.8M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $158.7M y $22.9M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$136.23m
Patrimonio	US$135.78m
Total pasivo	US$22.89m
Activos totales	US$158.67m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($140.9M) de CXF superan a sus pasivos a corto plazo ($22.2M).

Pasivo a largo plazo: Los activos a corto plazo de CXF ($140.9M) superan a sus pasivos a largo plazo ($644.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: CXF está libre de deudas.

Reducción de la deuda: CXF no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: CXF tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: CXF dispone de suficiente cash runway para 1.5 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 2.3% cada año.

Salud financiera de hoja de balance de Chimerix

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Recent updates

Third quarter 2024 earnings released: US$0.26 loss per share (vs US$0.27 loss in 3Q 2023)

Chimerix, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.21 loss in 2Q 2023)

Chimerix, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023)

Chimerix, Inc., Annual General Meeting, Jun 20, 2024

Chimerix, Inc. to Report Q1, 2024 Results on May 01, 2024

Chimerix Appoints Marc D. Kozin to Board of Directors

Full year 2023 earnings released: US$0.93 loss per share (vs US$1.97 profit in FY 2022)

Chimerix, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Chimerix Announces Board Changes

Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer

Chimerix, Inc. Appoints Michelle Laspaluto to Chief Financial Officer

Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer

Third quarter 2023 earnings released: US$0.27 loss per share (vs US$2.75 profit in 3Q 2022)

Chimerix, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.27 loss in 2Q 2022)

Chimerix, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023

Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth Index

CEO, President & Director recently bought €90k worth of stock

First quarter 2023 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2022)

Full year 2022 earnings released: EPS: US$1.97 (vs US$2.04 loss in FY 2021)

Insufficient new directors

Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study

Rubric Capital Management Sends Letter to Chimerix

Third quarter 2022 earnings released: EPS: US$2.75 (vs US$0.21 loss in 3Q 2021)

Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million.

Forecast to breakeven in 2022

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.21 loss in 2Q 2021)

Chimerix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

First quarter 2022 earnings released: US$0.28 loss per share (vs US$1.22 loss in 1Q 2021)

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.

Chimerix, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Chimerix, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative Announces Late-Breaking Oral Presentation At International Conference on Antiviral Research

Chimerix, Inc. Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in 3Q 2020)

Forecast to breakeven in 2023

Independent Director recently bought €65k worth of stock

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$1.22 loss per share (vs US$0.17 loss in 1Q 2020)

Full year 2020 earnings released: US$0.70 loss per share (vs US$2.03 loss in FY 2019)

Revenue misses expectations

Chimerix, Inc. Reports Topline Results from the First Cohort of Its Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study

New 90-day high: €8.81

New 90-day high: €7.91

Chimerix, Inc. (NasdaqGM:CMRX) acquired Oncoceutics, Inc. from Spring Mountain Capital, LP and others for $68.3 million

New 90-day high: €6.58

New 90-day high: €3.46

New 90-day high: €2.58

Revenue beats expectations

Third quarter 2020 earnings released: US$0.18 loss per share

Chimerix, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €1.93

New 90-day low - €2.22

New 90-day low - €2.47

First half earnings released

Chimerix, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway